Matthew Gall
2020
In 2020, Matthew Gall earned a total compensation of $1.9M as Chief Financial Officer at iTeos Therapeutics.
Compensation breakdown
| Bonus | $80,000 |
|---|---|
| Non-Equity Incentive Plan | $160,000 |
| Option Awards | $1,449,000 |
| Salary | $225,759 |
| Other | $1,500 |
| Total | $1,916,259 |
Gall received $1.4M in option awards, accounting for 76% of the total pay in 2020.
Gall also received $80K in bonus, $160K in non-equity incentive plan, $225.8K in salary and $1.5K in other compensation.
Rankings
In 2020, Matthew Gall's compensation ranked 5,708th out of 13,090 executives tracked by ExecPay. In other words, Gall earned more than 56.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,708 out of 13,090 | 56th |
Division Manufacturing | 2,358 out of 5,617 | 58th |
Major group Chemicals And Allied Products | 942 out of 2,248 | 58th |
Industry group Drugs | 816 out of 1,948 | 58th |
Industry Biological Products, Except Diagnostic Substances | 198 out of 411 | 52nd |
Source: SEC filing on May 5, 2021.
Gall's colleagues
We found two more compensation records of executives who worked with Matthew Gall at iTeos Therapeutics in 2020.